Trends in prescribing of sedative-hypnotic medications in the USA: 1993–2010

Pharmacoepidemiology and Drug Safety

Volumn 25, Issue 6, 2016, Pages 637-645

  Kaufmann, Christopher N ^a,b   Spira, Adam P ^a   Alexander, G Caleb ^a   Rutkow, Lainie ^a   Mojtabai, Ramin ^a  

^a JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

anxiety; pharmacoepidemiology; prescribing trends; sedative hypnotics; sleep

Indexed keywords

BENZODIAZEPINE DERIVATIVE; HYPNOTIC SEDATIVE AGENT; NON BENZODIAZEPINE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ADULT; ANXIETY DISORDER; ARTICLE; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAID; MEDICARE; MOOD DISORDER; PRESCRIPTION; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; PSYCHIATRIST; RACE; SLEEP DISORDER; UNITED STATES;

EID: 85027920375     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.3951     Document Type: Article

References (47)

1. Bertisch SM, Herzig SJ, Winkelman JW, Buettner C. National use of prescription medications for insomnia: NHANES 1999–2010. Sleep 2014; 37(2): 343–349. doi:10.5665/sleep.3410.
2. Costa e Silva JA. Sleep disorders in psychiatry. Metab Clin Exp 2006; 55(10 Suppl 2): S40–S44.
3. Allgulander C. History and current status of sedative-hypnotic drug use and abuse. Acta Psychiatr Scand 1986; 73(5): 465–478.
4. Food and Drug Administration. Ambien approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/nda/pre96/019908_S000_AP&AE_LTRS&FPL.pdf. Accessed June 18, 2014.
5. Food and Drug Administration. Sonata approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/1999/20859ltr.pdf. Accessed June 17, 2014.
6. Food and Drug Administration. Lunesta approval letter. http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2004/021476ltr.pdf. Accessed June 17, 2014.
7. Rossat A, Fantino B, Bongue B, et al. Association between benzodiazepines and recurrent falls: a cross-sectional elderly population-based study. J Nutr Health Aging 2011; 15(1): 72–77.
8. Mendelson WB. The use of sedative/hypnotic medication and its correlation with falling down in the hospital. Sleep 1996; 19(9): 698–701.
9. Ray WA, Griffin MR, Schaffner W, Baugh DK, Melton LJ. Psychotropic drug use and the risk of hip fracture. N Engl J Med 1987; 316(7): 363–369. doi:10.1056/NEJM198702123160702.
10. Herings RM, Stricker BH, de Boer A, Bakker A, Sturmans F. Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life. Arch Intern Med 1995; 155(16): 1801–1807.
11. Chen P-L, Lee W-J, Sun W-Z, Oyang Y-J, Fuh J-L. Risk of dementia in patients with insomnia and long-term use of hypnotics: a population-based retrospective cohort study. Forloni G, ed. PLoS One 2012; 7(11): e49113. doi:10.1371/journal.pone.0049113.
12. Peron EP, Gray SL, Hanlon JT. Medication use and functional status decline in older adults: a narrative review. Am J Geriatr Pharmacother 2011; 9(6): 378–391. doi:10.1016/j.amjopharm.2011.10.002.
13. Gray SL, LaCroix AZ, Hanlon JT, et al. Benzodiazepine use and physical disability in community-dwelling older adults. J Am Geriatr Soc 2006; 54(2): 224–230. doi:10.1111/j.1532-5415.2005.00571.x.
14. Gray SL, LaCroix AZ, Blough D, Wagner EH, Koepsell TD, Buchner D. Is the use of benzodiazepines associated with incident disability? J Am Geriatr Soc 2002; 50(6): 1012–1018.
15. Scharf MB, Roth T, Vogel GW, Walsh JK. A multicenter, placebo-controlled study evaluating zolpidem in the treatment of chronic insomnia. J Clin Psychiatry 1994; 55(5): 192–199.
16. Fairweather DB, Kerr JS, Hindmarch I. The effects of acute and repeated doses of zolpidem on subjective sleep, psychomotor performance and cognitive function in elderly volunteers. Eur J Clin Pharmacol 1992; 43(6): 597–601.
17. Langtry HD, Benfield P. Zolpidem. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential. Drugs 1990; 40(2): 291–313.
18. Rhalimi M, Helou R, Jaecker P. Medication use and increased risk of falls in hospitalized elderly patients: a retrospective, case-control study. Drugs Aging 2009; 26(10): 847–852. doi:10.2165/11317610-000000000-00000.
19. Allain H, Bentué-Ferrer D, Polard E, Akwa Y, Patat A. Postural instability and consequent falls and hip fractures associated with use of hypnotics in the elderly: a comparative review. Drugs Aging 2005; 22(9): 749–765.
20. Wang PS, Bohn RL, Glynn RJ, Mogun H, Avorn J. Zolpidem use and hip fractures in older people. J Am Geriatr Soc 2001; 49(12): 1685–1690.
21. Mellinger GD, Balter MB, Uhlenhuth EH. Insomnia and its treatment. Prevalence and correlates. Arch Gen Psychiatry 1985; 42(3): 225–232.
22. Wysowski DK, Baum C. Outpatient use of prescription sedative-hypnotic drugs in the United States, 1970 through 1989. Arch Intern Med 1991; 151(9): 1779–1783.
23. Zint K, Haefeli WE, Glynn RJ, Mogun H, Avorn J, Stürmer T. Impact of drug interactions, dosage, and duration of therapy on the risk of hip fracture associated with benzodiazepine use in older adults. Pharmacoepidemiol Drug Saf 2010; 19(12): 1248–1255. doi:10.1002/pds.2031.
24. NCHS. National Ambulatory Medical Care Survey Public Use Data File Documentation. ftp://ftp.cdc.gov/pub/Health_Statistics/NCHS/Dataset_Documentation/NAMCS/doc09.pdf [14 December 2015].
25. NCHS. About the Ambulatory Healthcare Surveys. http://www.cdc.gov/nchs/ahcd/about_ahcd.htm [14 December 2015].
26. Hsiao C-J. Understanding and using NAMCS and NHAMCS data: Data tools and basic programming techniques. http://www.cdc.gov/nchs/ppt/nchs2010/03_Hsiao.pdf [14 December 2015].
27. Mojtabai R, Olfson M. National trends in psychotropic medication polypharmacy in office-based psychiatry. Arch Gen Psychiatry 2010; 67(1): 26–36. doi:10.1001/archgenpsychiatry.2009.175.
28. Murray MP. Econometrics. Addison-Wesley: Boston, 2006.
29. Newey WK, West KD. A simple, positive semi-definite, heteroskedasticity and autocorrelation consistent covariance matrix. 1986.
30. Reinhold JA, Mandos LA, Rickels K, Lohoff FW. Pharmacological treatment of generalized anxiety disorder. Expert Opinion on Pharmacotherapy 2011; 12(16): 2457–2467. doi:10.1517/14656566.2011.618496.
31. American Psychiatric Association. Practice guideline for the treatment of patients with panic disorder, 1998.
32. Furtado C, Teixeira I. Benzodiazepine's utilization in continental Portugal (1999–2003). Acta Med Port 2006; 19(3): 239–246.
33. Tu K, Mamdani MM, Hux JE, Tu JB. Progressive trends in the prevalence of benzodiazepine prescribing in older people in Ontario, Canada. J Am Geriatr Soc 2001; 49(10): 1341–1345.
34. Walsh JK, Schweitzer PK. Ten-year trends in the pharmacological treatment of insomnia. Sleep 1999; 22(3): 371–375.
35. Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry 2014. doi:10.1001/jamapsychiatry.2014.1763.
36. Mojtabai R, Olfson M. Proportion of antidepressants prescribed without a psychiatric diagnosis is growing. Health Aff (Millwood) 2011; 30(8): 1434–1442. doi:10.1377/hlthaff.2010.1024.
37. Lunesta package insert. http://www.lunesta.com/pdf/PostedApprovedLabelingText.pdf. Accessed June 19, 2014.
38. Spanemberg L, Nogueira EL, da Silva CTB, Dargél AA, Menezes FS, Cataldo Neto A. High prevalence and prescription of benzodiazepines for elderly: data from psychiatric consultation to patients from an emergency room of a general hospital. Gen Hosp Psychiatry 2011; 33(1): 45–50. doi:10.1016/j.genhosppsych.2010.12.004.
39. Ahmer S, Salamat S, Khan RA, et al. Pattern of benzodiazepine use in psychiatric outpatients in Pakistan: a cross-sectional survey. Clin Pract Epidemiol Ment Health 2009; 5: 9. doi:10.1186/1745-0179-5-9.
40. Iqbal SP, Ahmer S, Farooq S, et al. Benzodiazepine use among adults residing in the urban settlements of Karachi, Pakistan: a cross sectional study. Subst Abuse Treat Prev Policy 2011; 6: 19. doi:10.1186/1747-597X-6-19.
41. Aparasu RR, Mort JR. Prevalence, correlates, and associated outcomes of potentially inappropriate psychotropic use in the community-dwelling elderly. Am J Geriatr Pharmacother 2004; 2(2): 102–111.
42. Glass J, Lanctot KL, Herrmann N, Sproule BA, Busto UE. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ 2005; 331(7526): 1169. doi:10.1136/bmj.38623.768588.47.
43. Buysse DJ, Germain A, Moul DE, et al. Efficacy of brief behavioral treatment for chronic insomnia in older adults. Arch Intern Med 2011; 171(10): 887–895. doi:10.1001/archinternmed.2010.535.
44. Jungquist CR, O'Brien C, Matteson-Rusby S, et al. The efficacy of cognitive-behavioral therapy for insomnia in patients with chronic pain. Sleep Med 2010; 11(3): 302–309. doi:10.1016/j.sleep.2009.05.018.
45. Olatunji BO, Cisler JM, Deacon BJ. Efficacy of cognitive behavioral therapy for anxiety disorders: a review of meta-analytic findings. Psychiatr Clin North Am 2010; 33(3): 557–577. doi:10.1016/j.psc.2010.04.002.
46. Kripke DF. Chronic hypnotic use: deadly risks, doubtful benefit. Sleep Med Rev 2000; 4(1): 5–20. doi:10.1053/smrv.1999.0076.
47. Hajjar ER, Cafiero AC, Hanlon JT. Polypharmacy in elderly patients. Am J Geriatr Pharmacother 2007; 5(4): 345–351. doi:10.1016/j.amjopharm.2007.12.002.